About

Srinath Adusumalli, MD, MSHP, MBMI, FACC, is an Associate Professor of Clinical Medicine in Cardiovascular Medicine at the Perelman School of Medicine and a Staff Cardiologist at the Hospital of the University of Pennsylvania. He also serves as an Adjunct Professor of Healthcare Management at The Wharton School. Dr. Adusumalli joined the Penn faculty in 2018 within the Division of Cardiovascular Medicine, focusing on health informatics initiatives, outpatient, inpatient, and imaging cardiology. His work includes implementing ambulatory telemedical care during the COVID-19 pandemic, managing custom applications such as Switchboard and Carelign, and developing research at the intersection of behavioral science and clinical decision support. He has held multiple leadership roles across Penn, including Assistant CMIO for Connected Health, Deputy Director of the Penn Medicine Nudge Unit, Director of the Penn Medicine-LDI Research Laboratory, and founding Director of the Penn Center for Cardiovascular Informatics. From 2022 to 2025, he served as Senior Medical Director for Health Informatics at CVS Health, overseeing enterprise projects like Epic implementation, clinical AI strategy, and virtual care initiatives. Dr. Adusumalli's research interests focus on leveraging technology to evaluate and accelerate evidence-based healthcare adoption, ensuring safety for patients and ease for clinicians. His projects include developing pathways for cardiac rehabilitation referral, deploying interventions for statin prescription, designing referral systems for advanced heart failure patients, and creating electronic reporting systems for cardiovascular procedures. He earned his medical degree from the Medical College of Virginia in 2011, completed internal medicine training at Massachusetts General Hospital in 2014, and his cardiovascular fellowship at the University of Pennsylvania in 2018, where he served as chief fellow. He also holds a Master of Science in Health Policy Research and a Master of Biomedical Informatics from the University of Pennsylvania. He is board certified in internal medicine, cardiovascular disease, clinical informatics, and echocardiography.

Research topics

• Internal medicine
• Medicine
• Environmental health
• Family medicine
• Emergency medicine
• Medical emergency
• Endocrinology
• Gerontology
• Cardiology
• Demography
• Virology

Selected publications

• Impact of a Noninterruptive Echocardiogram Report-Embedded Nudge on Rates of Referral to Cardiac Specialty Care and Aortic Valve Replacement in Patients with Severe Aortic Stenosis: A Multicenter Intervention

  Journal of the American Society of Echocardiography · 2026-02-19 · 2 citations

  articleOpen access

  BACKGROUND: Undertreatment of severe aortic stenosis (AS) including absence and delays in referral to cardiac specialty care remains common, particularly when patients are followed by noncardiac specialty providers. Electronic health record (EHR)-based nudges improve adherence to treatment but have not been widely evaluated in valvular heart disease. METHODS: In this multicenter study across 3 diverse US health systems, an automated, noninterruptive EHR-embedded nudge was implemented within the echocardiography report of patients with a first diagnosis (index echo) of severe AS. The study primarily targeted patients whose index echo was ordered by noncardiac specialty providers. The primary end point was referral to a cardiac specialist within 90 days. Secondary endpoints were a composite of completed cardiac specialty visit or aortic valve replacement (AVR) within 90 days, and AVR within 6 months. Analyses compared pre- and post-nudge cohorts using propensity score matching and multivariable logistic regression models. A difference-in-difference analysis was conducted to evaluate whether the nudge's effect differed by referring provider specialty (cardiac vs noncardiac). RESULTS: A total of 5,009 patients (mean age, 78 ± 11 years; 57% men, 88% White, 69% symptomatic) were identified. After propensity score matching (total n = 3,840; prenudge: 2,560 patients; postnudge: 1,280 patients), referral to cardiac specialty care increased from 94% prenudge to 97% postnudge (P < .001), and the composite outcome improved from 89% to 93% postnudge (P = .003). Among noncardiac specialty providers, all 3 outcomes of referral (89% to 96%, P < .001), composite outcome (83% to 88%, P = .017), and AVR within 6 months were higher postnudge (33% to 39%, P = .016). In the multivariable logistic regression model of the full cohort, the nudge was independently associated with higher odds of referral (adjusted odds ratio = 1.62; 95% CI, 1.15-2.30; P = .006) and composite outcome (adjusted odds ratio = 1.40; 95% CI, 1.10-1.79; P = .007), with a significant interaction indicating that the effect was most pronounced among noncardiac specialty providers (P < .001). CONCLUSION: A noninterruptive, scalable, EHR-embedded nudge within echocardiography reports improved referral to cardiac specialty care and treatment in patients with newly diagnosed severe AS, particularly among noncardiac specialty providers. These findings support the role of noninterruptive, automated nudges in standardizing guidelines-based care in severe AS.

  PublisherDOI

• Encouraging Pharmacist Referrals for Evidence-Based Statin Initiation

  JAMA Cardiology · 2025-03-26 · 5 citations

  articleOpen access

  Importance: Despite statins' benefit in preventing major adverse cardiovascular events, most patients with an indication for statin therapy are not appropriately treated. Clinicians' limited time and lack of systematic efforts to address preventive care likely contribute to gaps in statin prescribing. Objective: To determine the effect on statin prescribing of 2 interventions to refer appropriate patients to a pharmacist for lipid management. Design, Setting, and Participants: These 2 pragmatic cluster randomized clinical trials were conducted among 12 total primary care practices in a community health system. Trial 1 was a delayed-intervention design of a visit-based intervention with randomization at the clinician level in a single clinic, and trial 2 was a parallel-arm trial of an asynchronous intervention with randomization at the clinic level in 11 clinics. Patients who were assigned to a primary care clinician at a participating practice, had an indication for a high-intensity or moderate-intensity statin, and were either not prescribed a statin or prescribed an inappropriately low statin dose were eligible for inclusion. Intervention: Trial 1 tested an interruptive electronic health record alert that appeared during eligible patients' visits and facilitated referral to a pharmacist, while trial 2 tested an order for pharmacist referral placed by the study team for cosignature by the primary care clinician without regard to the timing of a clinic visit. Main Outcome and Measure: The primary outcome was the proportion of patients prescribed a statin. Results: Overall, 1412 patients were enrolled in trial 1 and 1950 in trial 2. Across both trials, mean (SD) patient age was 65.6 (9.9) years, and 1485 patients (44.2%) were female. Mean (SD) baseline 10-year risk of major cardiovascular events was 17.9% (9.4). In trial 1, the interruptive alert was not associated with a significant increase in statin prescriptions compared with usual care (15.6% vs 11.6%; unadjusted absolute difference, 3.9 percentage points; 95% CI, -0.4 to 8.3). In trial 2, semiautomated pharmacist referrals were associated with an increase in statin prescriptions by 16 percentage points compared with usual care (31.6% vs 15.2%; unadjusted absolute difference, 16.4 percentage points; 95% CI, 12.7-20.1). Conclusions and Relevance: In these 2 cluster randomized clinical trials, visit-based interruptive alerts were not associated with a significant increase in statin prescribing compared with usual care, whereas a strategy of asynchronous semiautomated referral for pharmacist comanagement was associated with a substantial increase. This strategy of asynchronous semiautomated referrals for pharmacist involvement in lipid management could be a scalable and effective approach to increasing statin prescribing for patients at high risk. Trial Registration: ClinicalTrials.gov Identifier: NCT05537064.

  PublisherOA PDFDOI

• Nudging the Needle — Strategies to Boost Influenza Vaccination Uptake

  NEJM Evidence · 2025-08-30

  letterSenior author
  PublisherDOI

• Utilization rates and determinants of PYP and CMR among patients with unexplained left ventricular hypertrophy on echocardiography

  International Journal of Cardiology · 2025-06-25 · 1 citations

  article
  PublisherDOI

• Surveillance Echocardiography in Severe Asymptomatic Aortic Stenosis: Guideline Adherence and Practice Patterns in a Multicenter Cohort

  Journal of the American Society of Echocardiography · 2025-10-09 · 1 citations

  article
  PublisherDOI

• TIMELY AORTIC VALVE REPLACEMENT IN SEVERE SYMPTOMATIC AORTIC STENOSIS: RATES AND CLINICAL IMPLICATIONS

  Journal of the American College of Cardiology · 2025-03-29

  articleOpen access
  PublisherDOI

• Referral patterns and clinical outcomes in patients with severe aortic stenosis: A multicenter cohort study

  American Heart Journal · 2025-07-22 · 4 citations

  articleOpen access

  BACKGROUND: Patients with severe aortic stenosis (AS) require timely follow-up by cardiac specialists and aortic valve replacement (AVR). This multicenter study evaluates how the specialty of the provider who ordered the initial echocardiogram influences these endpoints. METHODS: Patients from 3 health systems with a first echocardiogram (index echo) diagnosing severe AS from Jan 1, 2019 to Dec 31, 2022, were categorized based on the specialty of the provider ordering the echo. Endpoints included a composite outcome of early cardiac follow-up or AVR (within 90 days), AVR during follow-up, and mortality. Logistic regression and Cox proportional hazard models were used to identify factors associated with the endpoints. RESULTS: 4,249 patients (77 years; 58% male; 88% white; 72% symptomatic AS) were followed for a median of 552 days. Eighty-nine percent of patients achieved the composite outcome, yet 1,801 patients (42%) did not receive an AVR during the follow-up period, including 32% of symptomatic patients. Patients referred for the index echo by noncardiac specialty providers had lower rates of early cardiac follow-up or AVR (adjusted OR: 0.33, 95% CI, 0.25-0.43), lower AVR rates (adjusted HR: 0.59, 95% CI, 0.53-0.66), and higher mortality (adjusted HR: 1.65; 95% CI, 1.44-1.90) compared to the patients referred by a cardiology provider; the discrepancy was more pronounced in patients with low-flow, low-gradient AS. CONCLUSION: In this large multicenter study of patients with severe AS, patients with a noncardiac specialty provider were less likely to receive timely cardiac follow-up and AVR, and had higher mortality. Initiatives to address disparities in care and improve outcomes for this high-risk population are needed.

  PublisherDOI

• Cardiotoxicity from Bruton tyrosine kinase inhibitors (BTKi) – an analysis of an administrative health claims database

  Research Square · 2024-02-14

  preprintOpen access

  Abstract Background: First generation Bruton tyrosine kinase inhibitors (BTKi) such as ibrutinib have been associated with cardiovascular toxicities. Newer generation BTKi (e.g.,acalabrutinib and zanabrutinib) have been associated with lower incidence of cardiotoxicity in clinical trials. Objective: Given paucity in real-world data on the overall cardiac risk factor profile, especially with the newer BTKi, our study evaluated the incidence of cardiotoxicity with various BTKi among a large, commercially insured population of patients. Methods: We performed a retrospective cohort analysis of all adults with a diagnosis of B-cell malignancy undergoing treatment with BTKi acalabrutinib and ibrutinib between January 2018 and June 2020 using Optum’s de-identified Clinformatics® Data Mart Database. We then identified patients who had pre-existing cardiac disease one year prior to starting BTKi, and six months after starting BTKi to keep drug exposure rates similar. New incidence of atrial fibrillation/flutter, hypertension, bleeding, ventricular tachycardia/fibrillation and sudden cardiac death were compared with standard Chi Square or Student t-test where appropriate. Multivariate logistic regression models were also estimated to evaluate for confounding. Results: A total of 1691 patients were included in the final analysis. 1595 (94%, median age 75 (19–90) years, 61% male gender) patients received ibrutinib, and 96 (6%, median age 73.5 (32–90) years, 62.5% male gender) patients received acalabrutinib. The median duration of drug exposure of ibrutinib was 238 (2-1084) days vs 150 (30–870) days for acalabrutinib. There was lower new incidence of atrial fibrillation/flutter (4.6%-vs-17%, p = 0.014), hypertension (6.3%-vs-25%, p = NS), ventricular tachycardia/fibrillation (0% vs 1.5%, p = NS) in the acalabrutinib group within six months of drug exposure compared to ibrutinib, of which only the lower incidence of atrial fibrillation/flutter was statistically significant. This was despite the finding of a higher prevalence of atrial fibrillation/flutter at baseline in patients receiving acalabrutinib. Conclusions: There was lower incidence of new atrial fibrillation/flutter with acalabrutinib when compared to ibrutinib in a real-world cohort of patients.

  PublisherOA PDFDOI

• Two randomized controlled trials of nudges to encourage referrals to centralized pharmacy services for evidence-based statin initiation in high-risk patients: Rationale and design of the SUPER LIPID program

  American Heart Journal · 2024-04-26 · 4 citations

  articleOpen access
  PublisherOA PDFDOI

• Cardiotoxicity from bruton tyrosine kinase inhibitors (BTKi)—an analysis of an administrative health claims database

  Cardio-Oncology · 2024-06-01 · 6 citations

  articleOpen access

  BACKGROUND: First generation Bruton tyrosine kinase inhibitors (BTKi) such as ibrutinib have been associated with cardiovascular toxicities. Newer generation BTKi (e.g.,acalabrutinib and zanabrutinib) have been associated with lower incidence of cardiotoxicity in clinical trials. OBJECTIVE: Given paucity in real-world data on the overall cardiac risk factor profile, especially with the newer BTKi, our study evaluated the incidence of cardiotoxicity with various BTKi among a large, commercially insured population of patients. METHODS: We performed a retrospective cohort analysis of all adults with a diagnosis of B-cell malignancy undergoing treatment with BTKi acalabrutinib and ibrutinib between January 2018 and June 2020 using Optum's de-identified Clinformatics® Data Mart Database. We then identified patients who had pre-existing cardiac disease one year prior to starting BTKi. New incidence of atrial fibrillation/flutter, hypertension, bleeding, ventricular tachycardia/fibrillation and sudden cardiac death from the time of index presciption were compared with standard Chi Square or Student t-test where appropriate. Multivariate logistic regression models were also estimated to evaluate for confounding. RESULTS: A total of 1691 patients were included in the final analysis. 1595 (94%, median age 75 (19-90) years, 61% male gender) patients received ibrutinib, and 96 (6%, median age 73.5 (32-90) years, 62.5% male gender) patients received acalabrutinib. The median duration of drug exposure of ibrutinib was 238 (2-1084) days vs. 150 (30-870) days for acalabrutinib. There was lower new incidence of atrial fibrillation/flutter (4.6%-vs-17%, p = 0.013), hypertension (6.3%-vs-25%, p = NS), sudden cardiac arrest/death (0% vs. 1.5%, p = NS) in the acalabrutinib group compared to ibrutinib, of which only the lower incidence of atrial fibrillation/flutter was statistically significant. This was despite the finding of a higher prevalence of atrial fibrillation/flutter at baseline in patients receiving acalabrutinib. CONCLUSIONS: There was lower incidence of new atrial fibrillation/flutter with acalabrutinib when compared to ibrutinib in a real-world cohort of patients.

  PublisherOA PDFDOI

Frequent coauthors

• Peter W. Groeneveld

  Philadelphia VA Medical Center

  48 shared

• Lauren A. Eberly

  University of Pennsylvania

  46 shared

• Mitesh S. Patel

  Ascension

  44 shared

• Howard Julien

  University of Pennsylvania

  43 shared

• Sameed Ahmed M. Khatana

  University of Pennsylvania

  36 shared

• Neel Chokshi

  Penn Center for AIDS Research

  29 shared

• Ashwin S. Nathan

  28 shared

• Allison J. Hare

  Brigham and Women's Hospital

  27 shared

Education

• B.S., Biology and Economics

  Virginia Commonwealth University

  2006

• M.D.

  Virginia Commonwealth University

  2011

• M.S., Health Policy Research

  University of Pennsylvania

  2018

• Other

  University of Pennsylvania

  2021

Awards & honors

• Senior Fellow, Penn Leonard Davis Institute of Health Econom…
• Senior Fellow, Penn Institute for Biomedical Informatics